

Nutritional Treatment of Patients Operated on for Acute Mesenteric Ischemia

Timuçin Erol^{1,2}, [MD]

ORCID: 0000-0002-3475-3639

Şermin Ataç², [MD]

ORCID: 0000-0002-2940-3714

Kezban Akçay², [MD]

ORCID: 0000-0003-2848-3449

Nilgün Ölmez², [MD]

ORCID: 0000-0001-5823-8124

Nezih Akapulu¹, [MD]

ORCID: 0000-0001-7392-961X

Ahmet Doğrul¹, [MD]

ORCID: 0000-0001-9837-0787

Osman Abbasoğlu^{1,2}, [MD] ORCID: 0000-0001-7069-929X

¹Hacettepe University Faculty of Medicine Department of General Surgery

²Nutritional Support Department, Hacettepe University Hospital

Corresponding Author: Timuçin Erol Hacettepe University Faculty of Medicine Department of General Surgery & Nutritional Support Department, Hacettepe University Hospital. Phone: +90 312 305 16 76 E-mail: timucinerol@hacettepe.edu.tr

https://doi.org/10.32552/2021.ActaMedica.536

Received: 11 November 2020, Accepted: 15 March 2021, Published online: 25 March 2021

~ BSTRACT Com

Objective: Acute mesenteric ischemia is a surgical emergency. During the course of treatment, most of the patients require nutritional treatment. However, achieving nutritional goals may not be always possible. This study aimed to investigate nutritional management of the patients who were operated on for acute mesenteric ischemia.

Materials and Methods: Patients who were diagnosed and hospitalized for acute mesenteric ischemia between 2015 and 2018 were retrospectively analyzed. Nutritional management of patients was studied in terms of hospital length of stay, mortality rate and achieving of nutritional goals.

Results: Thirty patient were included in the study and 18 patient received nutritional treatment. Median length of stay was 28.5 (range:9-220) days. Target nutrition goals were only achieved in 11 patients (61%). Overall mortality rate for nutritional treatment group was 50%. There was no significant difference between the patients whose treatment objectives were achieved or failed in terms of length of stay (p=0.375) or mortality [(p=0.630 (95% Cl0,237-10,809)].

Conclusion: The management of nutritional treatment of acute mesenteric ischemia patients is challenging. Achieving the nutritional goals may not be possible in many patients.

Keywords: Mesenteric ischemia, short bowel syndrome, parenteral nutrition

INTRODUCTION

Acute mesenteric ischemia (AMI) is a sudden interruption of intestinal blood supply. Due to lack of collateral circulation, this situation often progresses to necrosis of bowel if early intervention is not performed. The incidence is quite low and diagnosis can be challenging. Delay in diagnosis is very common. Moreover, despite the utilization of endovascular techniques and appropriate

surgical treatment, morbidity and mortality rates are still high even in patients with early diagnosis [1]. Ischemia and the accompanying necrosis necessitates surgical intervention and resection of the necrotic bowel. The extent of resection depends on the amount of the bowel affected and can result in short bowel syndrome. Even in limited resections, patients may require nutritional treatment during

their hospital course. Most of these patients are old and have multiple co-morbidities which renders nutritional therapy even more challenging [2]. Under some circumstances, effective nutrition management may be more problematic due the patient's metabolic derangement. Interruptions of therapy and insufficient nutrient delivery are common problems in many patients [3].

In this study, we aimed to investigate the nutritional management of patients who were operated on for acute mesenteric ischemia in our center.

MATERIALS and METHODS

All patients diagnosed and hospitilised at general surgery department between 2015 and 2018

included to study included in this study. Patient's data retrospectively retrived from General Surgery Department data base which prospectively collect all operated patient's data. AMI was diagnosed by physical examination, laboratory tests, radiologic imaging, operative findings, and proved by histopathologic examination of resected bowel (Figure 1).

Patients' medical reports, operation notes, and prospectively recorded nutrition treatment follow up forms were analyzed retrospectively (Figure 2). Nutrition treatment aimed to reach 25 kcal/kg/d energy and 1.5 gr/kg/d protein to actual body weight. If the length of the remaining functional small bowel was less than 200 cm, in accordance with European Society of Parenteral and Enteral Nutrition(ESPEN) definition and classification of




Figure 1. Preoperative imaging and intraoperative findings

A, B: Computerized tomography angiography and 3-D reconstruction images showing a case of total occlusion of superior mesenteric artery. Red arrow indicates the level of occlusion

C, D: Intraoperative appearance of ischemic bowel and specimen after resection.

	EPE ÜNIVERSITESI		DIY	TİSYEN İZL	EM FORMU	*				1-11			
HASTAN	HASTANELERÍ			Section and Address of Marine			Tarama Nütrisyon Durumundaki Bozulma Hastalığın Siddeti (gereksininlerde artıs)						
Erişkin H Beslenme	lastanesi e Destek Birimi		HASTANIN	ten		Yek Sker 0	Normal nütrisyon durume		Yok Sker 0		esinsel gerek		
			# Adv. Sepath :			Hafif	3 ayda > %5 kilo kaybı ya ı	fa secen haftski	Haftif	Kalca Kem	niğinde Kırık		
			« Donya No :	let	Yage 1	Skar 1	besin abms normal gereksin %50-75'inin altında	nimberin	Skor 1		akut komplii	kasyonları olan	krynik
			. C. C.		Agenta :		%50-75 tein attinda					yelic, diabet, ani	lolof
			- 890 :		985	-	2 ayda > %5 kilo kaybı ya i	ta	Charles .			hit, innet,	
o İstemden O	Sine Taribi :		- Intenden Ding			Orta Skar 2	BKĪ 18.5 -20.5 × genet dur geçen haftaki besin alımı n	um bozukluğu ya da	Orta Skor 2	Siddlett pro	dmoni, heme	miqii nalignis	
Alreageleiği A		red Agerba c	- Hender And	Diseitifieris Ağırlıi			%25-50'vi	and processing to					
* Tany/Kin		nan mgorom :		'Annual share		Siddetti	1 ayda = %5 kito kaybı (3		Şiddetli			k Itigli transplar	stanyon
T.	in political)					Skor 3	BK2 + 16.5 + genel durum t geçen haftaki besin alımı s	borokloğu ya da sormal gereksinimlerin	Skar 3	Yogun Bolo	om Reptation ((APACHE = 10)	
2.							%0-251						
1.						Skers	40		Sker	- Toplam	sker		
4						Yag	>70 yas ise topiam skera 1	ekle	- 1010 00	erlanmış topla	am sker		
* Gardelleri	g Ameliyatlar :												
	,					Sker s3:	Hasta mitrlayon riski altındad	hr ve bir nütrisyon plan	n baqlatrire				
						Shor silt:	Haftada bir taranmah, Eğer m	ajór operasyon plam v	ena yine bir n	ütrioyen planı	n geliytirilm	elidir	
									40. 40.				
	AT ALL DE LINE					destekle	2 varolan randomize ktinik çal yen bir çalışma var. İtalik gös	terilen terriar yanda ve	rilen prototipi	lere dayanmal	ktadır, Nütri	tsyon riski, o ar	ndakli
* Yabipinda	ski Amellyatlar :					nütrisyon	durumu ve bunun stres metab	olioması nedeniyle arta	s gerekstelmle	re boğlı olarak	k bezulmanı	riski şeklinde ta	evelan
							n dertek plans şu hastalanda e						
						(1) (166)	etti malnütrioyonda (skor = 3)	, ya da (Z) ağır hasta i	sker = 3) ye d	la (3) orta de	rrecede male	sütrisyon + hafi	if hasta
							 ya da (4) hafif malnütrisyo m derecesine Wiskin prototipi 		- (sear 1 +2)				
							in derecessive (Uşkin prototişti Kroelik hastalığı olup kemplika		status trabas hi	r haste Marie	in district d	onestate see	A dilam
* Tedavi Pl	am :					olarak ya	rtaktan kalkabilir. Protein ger	eksinimlari artmıştır a	cak oral diyet	ya da suplen	manfarfa kan	planabilic,	-
							majile abdominal cerrahi gibi I			r hasta, Prote	rin gereksini	ledari yüksek, İ	divite
							e ybotemleri gerakli ve bu say						
						Skor-3: v	sentilasyon desteği altındaki ; smyor. Protein yıkımı ve azot	yoğun bakım hastası. P kaylıs giderliahttisin	rotein gereksi	ntmleri yükse	ek ve klinik i	bestenne yönte	mierly
						and branch	imper, resum passin re assi	Augus generalisation.					
-						m. de							
	E DESTEK TEDAVÍSÍ VERÍLÍ:	ž VOLU I				Tarth							
Onal						Presiber	-						
- Oran													
Enterel	DIS DIS DESCRIPTION	and Depart	the leading	Diğer		Albumin							
		4	other CO	- Delev		Albumin							
Enterel Perseter	nd Seetrel Perfect	4	etteri 🗆 🖸		48-715-bro-0,41-390								
Enteral Provider Gal. No. 41000	ni Sentrel Prefiteri	4	etteri 🗆 🖸			CRF	ASAMSAL BUIGUNAR	Tarih 1	uh !	Tarih	Tarih	Tarih	71
Enteral Persolani Esc.No. 41000 TEPE ÜNİVERSİTE Hastanesi Beslenm	ni Sentrel Prefiteri	4	etent 00	немуїле ігі		CRF	AŞAMSAL BULGULAR	Terih 1	uih :	Tarth	Tarih	Tark	71
Enterel Parenter Gal. No. 11000 TEPE Onliversite Mastanesi Beslenne oyadi:	ni Sentrel Prefiteri		elect GG	HEMŞİRE İZI İslam təribi:	LEM FORMU	CRF	AŞAMSAL BULGULAR	Tarih 1	wih :	Tarih	Tarih	Tarih	74
Enteral Parantes Furnites	ni Sentrel Prefiteri	Boy - Kilo:		HEMŞİRE İZI İslam təribi: Çıkış təribi:	LEM FORMU	(RF Y Ağırla	AŞAMSAL BULGULAR	Terih 1	wh :	Tarih	Tarih	Tarih	24
Forester Forester Fac.No. 41890 TTEPE ONLYERSITE Mastanesi Beslemme oyadi: a No: n/ode no:	ni Sentrel Prefiteri	Boy - Kilo: NRS 2002:		HEMŞİRE İZI İslam təribi: Çıkış təribi: Çıkış nadəni:	LEM FORMU	CRF	AŞAMSAL BULGULAR	Teris 1	irih :	Tarih	Tarih	Tarih	74
Enteral Paranters Ful. No. 410100 TEPE ONIVERSITE Maplanerii Beslemm oyadi: a No: Cincip statikilar: G-Yok	nd Gentral Profilerii ESİ HASTANELERİ In Destrak Birimi met: 3- 6. 3- 6.	Boy - Kilo: NRS 2002: Preablimin II		HEMŞİRE İZI İslem təribi: Çıkış təribi: Çıkış nedeni: Presibilenin s	LEM FORMU	(RF Y Ağırla		Tarih 1	urb.	Tarih	Tarih	Tarih	Ya
Enteral Paranters Ful. No. 410100 TEPE ONIVERSITE Maplanerii Beslemm oyadi: a No: Cincip statikilar: G-Yok	nd Gentral Profilerii ESİ HASTANELERİ In Destrak Birimi met: 3- 6. 3- 6.	Boy - Kilo: NRS 2002: Presbámin II CRP IIk:		HEMŞİRE İZI İslem taribi: Çıkış taribi: Çıkış nedeni: Prestiûnin s CRP son:	LEM FORMU	Y Aprile Ates		Tarih T	irb.	farih	Tarih	Tach	74
Entered Parantes Ear. Ro. 410100 TEPPE ONIVERSITE Mastanesi Beslenne oyadi: a No: N/oda no: Cinely satalitlar: G-Yok Tansar	nd Gentral Profilerii ESİ HASTANELERİ In Destrak Birimi met: 3- 6. 3- 6.	Boy - Kilo: NRS 2002: Presbámin II CRP IIk:		HEMŞİRE İZI İslem taribi: Çıkış taribi: Çıkış nedeni: Prestiûnin s CRP son:	LEM FORMU	Y Ağırlık Ateş KB (mını	nHg)	Tarih T	irh :	tarih	Tarih	Tach	74
Entered Paramters fur.fin. 410100 TEPE Onliversite Mastanesi Beslenne oyadi: a No: Cinsty statikilar: O-Yok Tanesi	nd Gentral Profilerii ESİ HASTANELERİ In Destrak Birimi met: 3- 6. 3- 6.	Boy - Kilo: NRS 2002: Presbámin II CRP IIk:		HEMŞİRE İZI İslem taribi: Çıkış taribi: Çıkış nedeni: Prestiûnin s CRP son:	LEM FORMU	Y Ağırlık Ateş KB (mını	nHg) m desteğl	Terb 1	irh :	Tarih	Tarih	Tach	7.
Entered Permeter Fort.No. 416460 TEPE GNİVERSİTE Mastanedi Beskenin oyedi: I. No: Clinsiy statiklur: O-Yok Tannası Ök öykönü:	nd Gentral Profilerii ESİ HASTANELERİ In Destrak Birimi met: 3- 6. 3- 6.	Boy - Kilo: NRS 2002: Presbámin II CRP IIk:		HEMŞİRE İZI İslem taribi: Çıkış taribi: Çıkış nedeni: Prestiûnin s CRP son:	LEM FORMU	CRP Ağırlık Ateş KB (mm Solumu Vazope	nHg) m desteğl	Terih 1	irh :	Tarih	Tarih	Tarih	Ti
Entered Permeter Fort.No. 416460 TEPE GNİVERSİTE Mastanedi Beskenin oyedi: I. No: Clinsiy statiklur: O-Yok Tannası Ök öykönü:	nd Gentral Profilerii ESİ HASTANELERİ In Destrak Birimi set: 3- 6. 3- 6.	Boy - Kilo: NRS 2002: Presbámin II CRP IIk:		HEMŞİRE İZI İslem taribi: Çıkış taribi: Çıkış nedeni: Prestiûnin s CRP son:	LEM FORMU	CRP Ağırlık Ateş KB (mm Solumu Vazope	nHg) m destrēji essor kullanumi	Tarih 1	ich	Tarih	Tach	Tarih	7.
Enteral Parameter Fort.No. 418400 TEPE ONIVERSITE Mastanesi Besiennes oyadi: No: Cincly statistiar O-Yok Tansa: Ok dyklosi:	al Sected Proflecti ESÎ HASTANELERÎ de Doublê Bîrîmi etc. 1- E. 2- E. 1- DAM 2- KDAH 3-	Boy - Killer MSS 2002: Preablished II CRP III:	k:	HEMŞİRE İzi İzlem taribi: Çıkış taribi: Çıkış nedeni: Presilikinin s CRP son:	LEM FORMU	Ağırlık Ateş KB (min Solumu Vizcope	nHg) m destrēji essor kullanumi	Tarih T	irb.	tech	Tach	Tark	Ti
Entered Percentage For No. 418400 TEPE Onlytersite Manhanesi Beslemm oyadi: No. Cinsip statistier: O-Yok Tamasi hit dyklord: ondaki giripimier: tima nedeni: 3- D:	al Seeted Perflerii ESÎ HASTANELERÎ de Destek Birinei ett: 1- E 2- E 1- DAA 2- KDAH 3-	Boy - Kills: NRS 2002: Preal/Sumin II CRP III: KIBH 4 KA	is 5- EXY	HEMŞİRE İZI İzlem taribi: Çıkış racibi: Çıkış nedeni: Presiblenin s CKP son: 6. NT 2-Kan	LEM FORMU See S. Diğer O destek	Ağırlık Ateş KB (min Solumu Vizcope	nHg) m desteği essor kullanımı BESLENME RAL BESLENME	Telh T	arth :	Tarih	Tarih.	Tach	7.
Entered Permeter Fort.No. 416460 TEPE GNÍVERSÍTE Mastaned Beskenne oyeth: I No: Closby stabiliar: O-Yok Tansac tik dyklósů: tima nedeni: 3- Di 6 - Bil	nd Seetral Perflerii ESİ HASTANELERİ es Coutak Birlini est: 3- K	Boy - Kills: NRS 2002: Preal/Sumin II CRP III: KIBH 4 KA	is 5- EXY	HEMŞİRE İZI İzlem tarihi: Çikş tarihi: Çikş redeni: Presibirini s CSP son: 6: NT 7- Kun testek 5- Postop	LEM FORMU See S. Diğer O Gestek	Ağırlık Ateş KB (mın Solumu Vazope ORAL ENTE! EN ürü	nHg) m desteği essor kullanımı BESLENME RAL BESLENME	Teris 1	irh :	Tarih	Tarih	Tach	7.
Entered Percenters Fort.No. 416160 TEPE ONIVERSITE Mastanesi Beslemm oyadi: No: Cinsty statistiar: Q- You Tanesi Né dyklind: disk dyklind: 6- Bil serilla yolu	al Gentral Profilerii ESİ HASTANELERİ al Dovutak Birlimi esti: 3- K. 3- E. 3- DAM 2- KIDAH 3- sofiqi) 2- Intensional Obs- liniç bozuk. 3- Karen içi enf. ENTERAL	Boy - Kilo: NRS 2002: PreafsGmin II CRP III: KIEM	k: 5- XXY 4- Preop d	HEMŞİRE İZI İzlam taribi: Çikiş taribi: Çikiş redeni: Predikirin s CRP son: 6- NT - 7- Kan erstek - 5- Postop n - 5- Diğer PARENITZAA	LEM FORMU See S. Diğer O Gestek	Ağırlık Ateş KB (mın Solumu Vazope ORAL ENTE! EN Grü Fiedeffi	nHg) m destriĝi essor kullanumi BESLENME RAL BESLENME	Terih 1	ich.	Tarih	Tarib	Tack	To
Externi Peranteri Peranteri Fort.No. 418100 TEPE ONIVERSITE Mastanesi Beslenesi oyadi: No: Cinsty statistism O-Yok Tanesi tik dykloid: di dykloid: 6 - Bil seriliş yolu tal yol 2 - Di	al Seeted Proflecti ESI HASTANELERI at Doubsit Shrimi ett 3- E 2- E 1- DAM 2- KDAH 3- rofuli 2- Interstinul Obs ling bonuk 7- Karen içi erf. ENTEAAL - NG 2- AD	Boy - Kilo: NRS 2002: Preablishini II CRP IIb: KRM - 8 - KAV	is 5- EXY	HEMŞİRE İZI İzlem taribi: Çünş taribi: Çünş redeni: Presibiomin s CRP son: 6- NT 7- Kan erstek 5- Postop n 5- Diğer PAMENITRAL	LEM FORMU Senti	Ağırlık Ateş KB (mınını Vazope ORAL ENTE! EN üribi Hedufii	midy) m desteği essor kullanımı	Tarih T	irb.	Tarih	Tach	Tack	7.
Externi Peranteri Peranteri Fort.No. 418100 TEPE ONIVERSITE Mastanesi Beslenesi oyadi: No: Cinsty statistism O-Yok Tanesi tik dykloid: di dykloid: 6 - Bil seriliş yolu tal yol 2 - Di	al Seeted Proflecti ESI HASTANELERI at Doubsit Shrimi ett 3- E 2- E 1- DAM 2- KDAH 3- rofuli 2- Interstinul Obs ling bonuk 7- Karen içi erf. ENTEAAL - NG 2- AD	Boy - Kilo: NRS 2002: PreafsGmin II CRP III: KIEM	t 5- XXY 4- Preop d 3-Perfocal	HEMŞİRE İZI İzlem taribi: Çikş teribi: Çikş redeni: Presibinin s CSP son: G: NT 7-Kun estek 5- Postop n 9- Diğer PARINTEAA © SOR: 3- Post 2	LEM FORMU Soon So Diğer O dertek L Diffickman 3- IfV	Ağırlık Ateş KB (mınını Vazope ORAL ENTE! EN üribi Hedufii	miligi m desteği essor kullanımı BESLENME RAL BESLENME n adı enen EN miktarı IN miktarı	Teh T	arth :	Tarih	Tarih	Tach	Ti
Entered Personner Got. No. 41990 TEPE ONIVERSITE Mastanesi Besienne oyede: 9 No: Cinely statistier O-Yok Tanes: hik dyklosis: sima nedeni: 1- Di merilis yolu col yol 2 systrottomi 2- systrottomi 2- systrottomi 2-	al Seeted Proflecti ESI HASTANELERI at Doubsit Shrimi ett 3- E 2- E 1- DAM 2- KDAH 3- rofuli 2- Interstinul Obs ling bonuk 7- Karen içi erf. ENTEAAL - NG 2- AD	Boy - Kilo: NRS 2002: Preablishin: II CRP Ib: XRM - 6 - KAO 4. 3- Ennibe - 8- Yetania; 3- Au 3- Radyolgiii	k: 5- XXY 4- Preop d	HEMŞİRE İZI İzlem taribi: Çikş teribi: Çikş redeni: Presibinin s CSP son: G: NT 7-Kun estek 5- Postop n 9- Diğer PARINTEAA © SOR: 3- Post 2	LEM FORMU Sents Sents Gestek L 2- Hickman 3- IfV 5- Femoral 6- FICC	Ağırtık Ateş EB (mın Vazope ORAL ENTE! EN ürb Hedeli Addığı Jugula	miligi m desteği essor kullanımı BESLENME RAL BESLENME n adı enen EN miktarı IN miktarı	Teris 1	irh :	Tarih	Tarih	Tach	7.
Externi Perenteri Perenteri Fort.No. 418100 TEPE ONIVERSITE Mastanesi Beslenesi oyadi: No: Cinely statistism G-Yok Tanesi bik dykūnū: S-Di serilis yolu sal yol	al Seeted Profilerii ESÎ HASTANELERÎ el Doubek Bîrimi est: 3- E. 2- E. 1- DAM 2- KDAH 3- infaji 2- intensinul Obu- linç bonuk. 2- Karen içi erf. ENTEAAL - NG 2- AD - Aça 2- PEG	Boy - Kilo: NRS 2002: Preablishin: II CRP Ib: XRM - 6 - KAO 4. 3- Ennibe - 8- Yetania; 3- Au 3- Radyolgiii	4: Freep d 4: Preep d 3: Periferal 2: Santral	HEMŞİRE İZI İzlem taribi: Çünş taribi: Çünş taribi: Çünş redeni: Presibilinin s CKP son: 6- NT 7- Kan hertek 5- Postop n 5- Diğer PARINIZAR O Süre: 1- Port 2 4-50V 5 0 Kanster taribi:	LEM FORMU Sents Sents Gestek L 2- Hickman 3- IfV 5- Femoral 6- FICC	Ağırtık Ateş EB (mın Vazope ORAL ENTE! EN ürb Hedeli Addığı Jugula	noNg) m desteği essor kullanımı BESLENME RAL BESLENME n adı none EV miktarı UN miktarı ma has	Terb 1	ich :	Tarih	Tarih	Tech	Ti
Entered Paramter Gor.Ao. 41000 TTEPE ONIVERSITE Mastanesi Beslenne oyeale a No. Cinsiy statiklar O Yok Tanas: olik dyklosi: sima nedeni: 1- Di 6 - Bil serilla yolu sitriyoli 1 sitriyoli 2 sitriyoli 2 sitriyoli 2 sitriyoli 2 sitriyoli 2 sitriyoli 3	al Seeted Profilerii ESÎ HASTANELERÎ el Doubek Bîrimi est: 3- E. 2- E. 1- DAM 2- KDAH 3- infaji 2- intensinul Obu- linç bonuk. 2- Karen içi erf. ENTEAAL - NG 2- AD - Aça 2- PEG	Boy - Kilo: NRS 2002: Preablishin: II CRP Ib: XRM - 6 - KAO 4. 3- Ennibe - 8- Yetania; 3- Au 3- Radyolgiii	4: Freep d 3: Perfocal 3: Ferfocal To Santral Hedel kalon/jv	HEMŞİRE İZI İslem tarihi: Çileş nedeni: Presibilenin s CKP son: 6- NT 2- Kan estek 5- Postop n 5- Diğer PARINITERA D Süre 1- Purt 2 4-550** 1- Konter tarihi: Optimi	LEM FORMU Sents Sents Gestek L 2- Hickman 3- IfV 5- Femoral 6- FICC	Ağırlık Ateş EB (non Solumus Vizzope ORAL ENTEI EN Größ Adığı E Uygula Su Ek mod Ek mod	noNg) m desteği essor kullanımı BESLENME RAL BESLENME n adı none EV miktarı UN miktarı ma has	Tarih T	irb.	Tarih	Tach	Tack	71
Entered Formation Formation Formation Formation Formation Formation Formation Formation Formation Formation Formation Clinity statistics Clinity statistics Clinity statistics Clinity statistics Clinity statistics Formation Formati	al Seeted Profilerii ESÎ HASTANELERÎ el Doubek Bîrimi est: 3- E. 2- E. 1- DAM 2- KDAH 3- infaji 2- intensinul Obu- linç bonuk. 2- Karen içi erf. ENTEAAL - NG 2- AD - Aça 2- PEG	Boy - Kilo: NRS 2002: Preablishin: II CRP Ib: XRM - 6- KAV 4- S- Ennible - 8- Yetania; 3- Na 3- Radyolgiii	4: Freep d 4: Preep d 3: Periferal 2: Santral	HEMŞİRE İZI İzlem taribi: Çikş taribi: Çikş redeni: Presibinin s CEP son: 6- NT - 7- Kun estek - 5- Postop n - 9- Dijer PARENTERA O SON: 2- 4-50V - 5 0- Kateler taribi: Vjerotein:	LEM FORMU Sents Sents Gestek L 2- Hickman 3- IfV 5- Femoral 6- FICC	Ağırlık Ateş EB (men Solumus Vazope ORAL ENTEI EN Größ Adığı t Uygula Sol Ek med Gaetrik PARE	nong) m desteği mesor kullanımı BESLENME RAL BESLENME n adı nonen Eli miktarı Un miktarı ma has Niller Grün residiü	Tech T	arth :	Tarih	Tarih	Tack	71
Entered Percenters For Ann. 41990 TEPE ONIVERSITE Maytaned Beslemm oyade: a No: Constly statistier: O-Yok Tanea: site oyade: coduki giriginder: sites nedeni: 3- D: 6- Bil serritg yolu coli yol 3 serrestomi 3- f salori/protein: digi lalori/protein: fe sligma dununu:	al Seeted Profilerii ESÎ HASTANELERÎ el Doubek Bîrimi est: 3- E. 2- E. 1- DAM 2- KDAH 3- infaji 2- intensinul Obu- linç bonuk. 2- Karen içi erf. ENTEAAL - NG 2- AD - Aça 2- PEG	Boy - Kilo: NRS 2002: Preablishin: II CRP Ib: XRM - 6- KAV 4- S- Ennible - 8- Yetania; 3- Na 3- Radyolgiii	&: 5 SXY 4 Proop of [ginensis oral also 3 Perfecal 2 Santral Hedel kalon/ly Alsohidgi kalon	HEMŞİRE İZI İzlem taribi: Çikş taribi: Çikş redeni: Presibinin s CEP son: 6- NT - 7- Kun estek - 5- Postop n - 9- Dijer PARENTERA O SON: 2- 4-50V - 5 0- Kateler taribi: Vjerotein:	LEM FORMU Sents Sents Gestek L 2- Hickman 3- IfV 5- Femoral 6- FICC	Ağırlık Ateş KB (mm Vazopp ORAL ENTE! EN ürü Hedefit Aldığı E Uygula Su Ek med Gastırık PARE	midej mi desteği essor kullanımı BESLENME RAL BESLENME n sib enen EN miktarı Nı miktarı ma has Nüfer ürün recidü NTERAL BESLENME	Teris 1	irih :	Tarih	Tarih	Tach	7.
Entered Permiter Perm	al Seeted Profilerii ESÎ HASTANELERÎ el Doubek Bîrimi est: 3- E. 2- E. 1- DAM 2- KDAH 3- infaji 2- intensinul Obu- linç bonuk. 2- Karen içi erf. ENTEAAL - NG 2- AD - Aça 2- PEG	Boy - Kilo: NRS 2002: Preablishin: II CRP Ib: XRM - 6- KAV 4- S- Ennible - 8- Yetania; 3- Na 3- Radyolgiii	&: 5 SXY 4 Proop of [ginensis oral also 3 Perfecal 2 Santral Hedel kalon/ly Alsohidgi kalon	HEMŞİRE İZI İzlem taribi: Çikş taribi: Çikş redeni: Presibinin s CEP son: 6- NT - 7- Kun estek - 5- Postop n - 9- Dijer PARENTERA O SON: 2- 4-50V - 5 0- Kateler taribi: Vjerotein:	LEM FORMU Sents Sents Gestek L 2- Hickman 3- IfV 5- Femoral 6- FICC	Ağırlık Ateş KB (mm Vazopp ORAL ENTE! EN ürü Hedefit Aldığı E Uygula Su Ek med Gastırık PARE	nong) m desteği mesor kullanımı BESLENME RAL BESLENME n adı nonen Eli miktarı Un miktarı ma has Niller Grün residiü	Terb 1	ich :	Tarih	Tarih	Tack	70
Entered Percentage For Ann. 41890 TEPE Onlytersite Mastaneol Besterne oyani: No: Cinsip statistier: O-Yok Taneol hit dyklorid: 6-80 entility yolk all-yol statistier: J- juncatomi J- kutorsjorotem: Gijj kalon/protein: k	al Seeted Profilerii ESÎ HASTANELERÎ el Doubek Bîrimi est: 3- E. 2- E. 1- DAM 2- KDAH 3- infaji 2- intensinul Obu- linç bonuk. 2- Karen içi erf. ENTEAAL - NG 2- AD - Aça 2- PEG	Boy - Kilo: NRS 2002: Preablishin: II CRP Ib: XRM - 6- KAV 4- S- Ennible - 8- Yetania; 3- Na 3- Radyolgiii	&: 5 SXY 4 Proop of [ginensis oral also 3 Perfecal 2 Santral Hedel kalon/ly Alsohidgi kalon	HEMŞİRE İZI İzlem taribi: Çikş taribi: Çikş redeni: Presibinin s CEP son: 6- NT - 7- Kun estek - 5- Postop n - 9- Dijer PARENTERA O SON: 2- 4-50V - 5 0- Kateler taribi: Vjerotein:	LEM FORMU Sents Sents Gestek L 2- Hickman 3- IfV 5- Femoral 6- FICC	Ağırtık Ateş KB (men Solumu Vazope ORAL ENTE! EN ürün Hedefi Hedefi Su Ek med Gaetrik PARE	nekje) m destejli essor kullanums .BESLENME .RAL BESLENME .n off	Tarih T	irb.	Tarih	Tach	Tech	To The
Entered Percentage For Ann. 41890 TEPE Onlytersite Mastaneol Besterne oyani: No: Cinsip statistier: O-Yok Taneol hit dyklorid: 6-80 entility yolk all-yol statistier: J- juncatomi J- kutorsjorotem: Gijj kalon/protein: k	al Seeted Profilerii ESÎ HASTANELERÎ es Doubsă Birlinei est: 3- E. 2- E. 1- DAM 2- KDAH 3- infaji 2- Interstinul Obu- linç bonuk. 2- Karen içi erf. ENTEAAL - NG 2- AD - Aça 2- PEG	Boy - Kilo: NRS 2002: Preablishin: II CRP Ib: XRM - 6- KAV 4- S- Ennible - 8- Yetania; 3- Na 3- Radyolgiii	&: 4. Preop d [glinensis oral als 3. Perfecal 2. Santral Heder kalon/ly Alsbirdig kalor Hederly uluşma	HEMŞİRE İZI İzlem taribi: Çikş taribi: Çikş redeni: Presibinin s CEP son: 6- NT - 7- Kun estek - 5- Postop n - 9- Dijer PARENTERA O SON: 2- 4-50V - 5 0- Kateler taribi: Vjerotein:	LEM FORMU Sents Sents Gestek L 2- Hickman 3- IfV 5- Femoral 6- FICC	Ağırlık Ateş KB (mm Viziope ORAL ENTE! EN ürü Hedefit Aldığı E Üygüla Su Gastrik PARE Hedefit Aldığı F	nekje) m destejli essor kullanums .BESLENME .RAL BESLENME .n off	Tarih T	arth :	Tarih	Tarih	Tack	74
Entered Parantee For Ann. +18100 TEPE ONIVERSITE Restanced Bestemm pyach: Nec Vode no: Cinsip stabilite: O-Yok Taneet like dyklord:	al Seeted Profilerii ESÎ HASTANELERÎ es Doubsă Birlinei est: 3- E. 2- E. 1- DAM 2- KDAH 3- infaji 2- Interstinul Obu- linç bonuk. 2- Karen içi erf. ENTEAAL - NG 2- AD - Aça 2- PEG	Boy - Kilo: NKS 2002: Preshismin II CRP Bit KIRM - B. CAN E B. Ennible B. Yetarili; J- All J- Radyolgili mi	&: 4. Preop d [glinensis oral als 3. Perfecal 2. Santral Heder kalon/ly Alsbirdig kalor Hederly uluşma	HEMSIRE IZI Islam sarihi Çikış tarihi: Çikış nedeni: Presilikinin s CRP son: G. NT 7- Kun 9- Diger. PARENTERAL Diore: 1- Port 2 4-507 S Konerer tarihi: Osterii.	LEM FORMU Sents Sents Gestek L 2- Hickman 3- IfV 5- Femoral 6- FICC	Aprilik Atep Solumn Vazope ORAL ENTE! EN Grib Heddelik Sig Ex med Gaetrik PARE Heddelik Aidig E	milet m destell essor kullanum BESLENIME RAL BESLENIME n ald sone EN miletan In miletan ma hus Noter Grün recidil NTERAL BESLENIME sone PN miletan 'N miletan 'N miletan	Tech T	irith !	Tarih	Tarih	Tach	To
Entered Personner For Ann. 41890 TEPE Onliversite Mastaneol Bestemm oyed: S No: Closiy statistier G Yok Tames nik dykdod: chia projenier: tima nedeni: 2- Di s- Bil serilig yolu cili yol statistier J junctioni: 2- I junctioni: 2- I junctioni: 3- I juncti	IS Seetral Perflerii IS HASTANELER IS Device Strimi INTERNAL Perflerii INTE	Boy - Kilo: NR3 2002: Preshismin II CRP Bit. S. Snoube S. Yetarili; 3- All ROMPLIKASY	&: 4. Proop of Iglioensis oral als 3. Perifecal 2. Santral Heder kalon/ly Alabitdiji kalor Hederle ulisyma	HEMSIRE IZI Islam sarihi Çikış tarihi: Çikış nedeni: Presilikinin s CRP son: G. NT 7- Kun 9- Diger. PARENTERAL Diore: 1- Port 2 4-507 S Konerer tarihi: Osterii.	LEM FORMU Sent S- Diğer destek L 2- Hickman 3- IIV 5- Fence 4- FICC 10 Cept	Aprilik Aheq RB (men Vaxope ORAL ENTE! EN Gro Hedelik Su Ex mod Gastrix PARE Hedelix Aldig E Hedelix Aldig E Hedelix Aldig E Hedelix Aldig E RCARA	m destreji essor kullanımı BESLENME RAL BESLENME nodi nodi nom EN miktarı IN miktarı ma hus Nüfer Grün rezidü NTERAL BESLENME enen PN miktarı 'N miktarı	Teris 1	irth .	Tarih	Tarih	Tack	70
Enteral Perenter For Ann. +16400 TEPE GNIVERSITE Restance: Beskenne pyeds: Nos: Clossly statistium O-Yok Ennes: Isk dyklord: Ima nedeni: 1- Di 6 - Bil serilija yolu ali - Bi	al Seeted Profilerii ESÎ HASTANELERÎ es Doubek Birinei est: 3- E. 2- E. 1- DAM 2- KDAH 3- info bonuk. 2- Karen içi erf. ENTERAL AÇA 2- RÇÖ AÇA 2- RÇÖ AÇA 2- RÇÖ ENTERAL	Boy - Kilor NRS 2002: Preafsümin II CRP III CRP III L. 3- Emilibe S- Yetarrili J- Au J- Audyolojili mi	&: 4- Preop d fgiorensis oral also 3- Ferifecal 3- Santral Heddirk slispma ONLAR Dripin Yolu Hisamman	HEMSIRE IZI Izlem taribi: Çikış taribi: Çikış taribi: Çikış redeni: Presibininin si CKP son: 6- NT 2- Kan 6- NT 2- Kan 6- NT 2- Kan 9- Diğer PARENTERA © Süre: 1- Port 2 4-5KV 2 4-5KV 2 4-5KV 3 © Kanter taribi: Vjerotoin: Gurumu:	LEM FORMU Sent S- Diğer O destek L 2- Prockman S- IV S- Fect S- Diger ENTERAK Erigim Yolu S- Feat	Ağırtık Ateş RB (mın Solumu Vazope ORAL ENTE! EN ürü Hedefi Adığı Su Ek mod Gastrik PARE Hedefi Hedefi NG\Ge Kusma	m destreji essor kullanımı BESLENME RAL BESLENME nodi nodi nom EN miktarı IN miktarı ma hus Nüfer Grün rezidü NTERAL BESLENME enen PN miktarı 'N miktarı	Tarih T	irb.	Tarih	Tarib.	Tech	70
Entered Forester Governorment G	Sentral Perfleri ESI HASTANELERI Re Devotak Birlinsi Ret 1- K 2- E 1- DAA 2- KDAH 3- RATEAAL Apa 2- RG Apa 2- RG Apa 3- G/Rejunostov ENTERAL Metsbolik I Ingensteren Gentraleri	Boy - Kilo: NRS 2002: Preafisionini II CRP III: L. 3- Ennibe S- Yetania; J- Au J- Rodyolgin mi KOMPLINASY	4: Preop d Gligibrenst oral all 3: Periferal 2: Santral Hedel kalon/ly Hedel's sligma ONLAR Cripin Yolo	HEMSIRE IZI Islam taribbi Çikış taribbi Çikış taribbi Çikış nedeni: Presibininin si CKP son: 6- INT 7- Kan 9- Diğer PARENTERAL D Süre: 1- Port 2 4- SKV 2 4- S	LEM FORMU Sees 8- Diğer O destek L O-rickman 3- Isv Femoral 6- PICC II Cepic ENTERAL Engin Yolu II reste	Ağırtık Ateş EB (men Solumus Vazope ORAL ENTE! EN Grb Heddefi Aldığı E Uygub Su Ek mod Gastrik PARE Heddefi Aldığı F CRAR İdrar NG/Ge Kusma	m destreji essor kullanımı BESLENME RAL BESLENME nodi nodi nom EN miktarı IN miktarı ma hus Nüfer Grün rezidü NTERAL BESLENME enen PN miktarı 'N miktarı	Tarih T	arth !	Tarih	Tach	Tack	70
Entered Personner For Ann. 416409 TEPE (INIVERSITE Maykanesi Beskenne oyade: a No: Closby stelliklar: D. Yok Tanasi olik dyklosi: Iniversity yolu coli yol	at Seetest Profilerit ESI HASTANELERE at Doubsk Shrind etc. 3- E. 3- E. 1- DAM 2- KDAH 3- Interstinal Obs. ENTERAL AGR. 2- AGR. AGR. 2- AGR. AGR. 3- AGR. ENTERAL Missbolik GRannick GRannick ENTERAL Missbolik	Boy - Kilo: NR3 2002: Preshismin II CRP Bit KIRM & CAA L. 3- Ennible B. Yetarili; 3- All B- Rodyolgib mi ROMPLIKASY T Tip T	&: 4. Proop of figlioensis oral als 3. Perifecal 2. Santral Heder kalon/ly Alabitidgi kalor Hederle uluşma CONLAR Irişim Yolu Hamması şyarandası şyarandası şyarandası şyarandası	HEMŞİRE İZI İslem tarihi Çiliş redeni. Çiliş redeni. Presibinin s CEP son: G. NT 7- Kun bestek 5- Postop 9- Diğer PARINITEAL O Süre 1- Post 2 4-55V 5 0 Katerer tarihi dürumu: PARINITEAL Metabolis O Siper PARINITEAL O Süre O Süre O Katerer tarihi O Katerer tarihi O Katerer tarihi O Katerer tarihi O Katerer tarihi O Katerer tarihi O Katerer tarihi O Katerer tarihi O Katerer tarihi O Süre O Süre O Süre O Süre O Katerer tarihi	LEM FORMU Sension O destak L Prickman 3- Inv Femoral 6- PICC Cape ENTERAL Englan Yolu Flads Flads Flads Charles	Ağırtık Ateş RB (mın Solumu Vazope ORAL ENTE! EN ürü Hedefi Adığı Su Ek mod Gastrik PARE Hedefi Hedefi NG\Ge Kusma	m destreji essor kullanımı BESLENME RAL BESLENME nodi nodi nom EN miktarı IN miktarı ma hus Nüfer Grün rezidü NTERAL BESLENME enen PN miktarı 'N miktarı	Tech T	arth :	Tarih	Tarih	Tach	71
Entered Percenters Fort.No. 416469 TEPE ONIVERSITE Mastanesi Besienne oyadi: In No. Cinsty statistiar: Q- You Tanesi Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk dykloui: Isk disk dykloui: Isk dy	Sentral Profilerii ESI HASTANELERII IN Drivitali Birlimi INTERAL Sentral J. E. J. E. J. DAA J. KISAH J. INTERAL Metabolii CHERAL Metaboli	Boy - Kilor NES 2002: PreafsGmin II CRP Ibr. CRP Ibr. S. Yetarrila J- Au J- Audyotajii mi KOMPLIKADY Tilg Til	& S- XXY & Preop d [glivensis oral also]-Perifecal]-Santral Nederla dispria Nederla dispria ONLAR CHAR Upparate ONLAR	HEMSIRE IZI Islam sarishi Çikış tarishi: Çikış nedeni: Presilikimin s CRP son: G. NT 7- Kun 9- Düre: PARENTERAL Düre: 1- Port 2 4-507 3 G. Konter-tarishi: durumu: PARENTERAL Option: 1- Port 2 4-507 3 G. Konter-tarishi: durumu: PARENTERAL P	LEM FORMU Sent S. Diğer O destek L D. Hickman 3- IV Frence G-PICC Cape: EntiteAc Engim York D habit D	Ağırtık Ateş EB (men Solumus Vazope ORAL ENTE! EN Grb Heddefi Aldığı E Uygub Su Ek mod Gastrik PARE Heddefi Aldığı F CRAR İdrar NG/Ge Kusma	ninke) mi desteği sesori kullanımı BESLENME RAL BESLENME n adı sonon EN miktarı Nı miktarı ma hes Niller ürün nesidü NTERAL BESLENME sonon PN miktarı Nı miktarı	Teris 1	irth .	Tarih	Tarih	Tack	Ti
Entered Personner Fortino 416400 TEPE Onlytersite Mastanesi Beslenne oyed: I No: Closty statistur: 0-Yok Tanes Ok dyklinis: Innellig yole 6-80 entilig yole 12- particulare 2- particulare 3- particulare 4- particulare 5- particulare 6- particulare 6- particulare 7- particulare 6- particulare 6- particulare 7- particulare 6- particulare 7- particulare 6- particulare 7- particulare 6- particulare 7- particulare 6- particulare 7- particulare 6- particulare 7- particulare 6- particulare 7- particulare 6- particulare 7- particulare 6- particulare 7- particulare 7- particulare 7- particulare 9- partic	Sentral Profilerii ESI HASTANELERI at Double Strind Set 3- E 3- E 3- E 3- DM 2- KDAH 3- Interstinal Observation of Christope of Chr	Boy - Kilox NRS 2002: Preshivmin II CRP Ris. KISH 4 - KAO 5 - Sernible 5 - Yetersia; 3 - Au KOMPLİKADY KOMPLİKADY 1 - Tilg 1	A: S- SXY 4- Preop d glovensis oral all 3- Ferifacel 2- Santral Hedel kalon/pla Hedel's uluşma CONLAR CONLAR Conlama paraması pa	HEMSIRE IZI Islam taribi: Çikış taribi: Çikış taribi: Çikış redeni: Presificinin s CKP son: 6- INT 2- Kan 6- INT 2- Kan PARINTERAL D Süre: 1- Port 2 4-SKV: 1- Port 2 4-SKV: 1- Port 4 4-SKV: 1- Port 4 4-SKV: 1- Port 4 4-SKV: 1- Port 4 4-SKV: 1- Port 5 1- Port 6 1- Port 1 1 1- Port 1 1 1- Port 1 1 1- Port 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	LEM FORMU Sension O destak L Prickman 3- Inv Femoral 6- PICC Cape ENTERAL Englan Yolu Flads Flads Flads Charles	CRF Agerial Ateg EB (non Solume Vazope ORAL ENTEI EN Grö Meddfi Aldgb E Uygob Ek mod Gaotrik Aldgb F CDKAR Idrar NG/GB Kusma Dren Fierbil	midej mi desteği essor kullanımı BESLENME RAL BESLENME n sib enen EN miktarı Nı miktarı ma has Nüfer ürün recidü NTERAL BESLENME enen PN miktarı Nı miktarı	Tarih T	irb.	Tarih	Tach	Tech	71
Entered Permeter Fort.No. 416400 TEPE (INIVERSITE Maphanesi Beshemm oyadi: INIVERSITE Maphanesi Beshemm oyadi: INIVERSITE Maphanesi Beshemm oyadi: INIVERSITE Maphanesi INIVERSITE INIVERS	Sentral Profilerii ESI HASTANELERII IN Drivitali Birlimi INTERAL Sentral J. E. J. E. J. DAA J. KISAH J. INTERAL Metabolii CHERAL Metaboli	Boy - Kilo: NES 2002: Preablishin II CRP Ib: XIM	A: S- XXY 4- Preop d (glioensis oral also 3- Ferifical 2- Santral Hederik siloyma Note in the siloyma ONLAR (rojim Yolu 1-tianimae 1-piamae 1-pi	HEMSIRE IZI Islam sarishi Çikış tarishi: Çikış nedeni: Presilikimin s CRP son: G. NT 7- Kun 9- Düre: PARENTERAL Düre: 1- Port 2 4-507 3 G. Konter-tarishi: durumu: PARENTERAL Openii: Gurumu: Gurumu: Gurumu: Gurumu: PARENTERAL Openii: Gurumu	LEM FORMU Sees 8- Diger Sees 8- Diger Description 3- Inv Frenchical 6- PICC Coper ENTERAS, Erigina Yorku Frenchical Coper Control Coper Control Coper Control Coper Control Coper Control Coper Control Coper Control Coper Control Coper Coper Control Coper Control Coper Control Coper Control Coper Coper	Ağırtık Ateş KB (mının Vazope ORAL ENTE! EN ürü Hedelifi Addığı E Lygula Su Ek med Gastırık Hedelifi Aldığı F CKAR İdrar NG/Ga	midej mi desteği essor kullanımı BESLENME RAL BESLENME n sib enen EN miktarı Nı miktarı ma has Nüfer ürün recidü NTERAL BESLENME enen PN miktarı Nı miktarı	Tarih T	arth :	Tarih	Tach	Tack	To
Entered Percenters Formation Formati	Sentral Profilerii ESI HASTANELERII Devotas Birlind Devotas Birlind Destas Sentral DEST S. E. J. E. J. DAR. J. KISAH J. ENTERAL ENTERAL Metabolis Disponstremi Publisherii Disponstremi Publi	Boy - Kilox NRS 2002: Preshibmin II CAP Bit KISH	A: Preop d 4: Preop d 3: Periferal 2: Santral Theder kalori/p Alabitidg kalor Hederfe uluşma Theman CONLAR CO	HEMSIRE IZI Intern taribi: Chiq taribi: Chiq nedeni: Presidenin i CEP son: 6. NT 7-Kan FARNITEAL Sign: 1-Port 2 4-SeV 5 5-Capter PARNITEAL Sign:	LEM FORMU Sees 8: Diğer Sees 8: Diğer D. Mickenson 3- IVV S. Fernickal 6- PICC II Capit ENTERAC Erigim York C Fance C Falcons C Falco	Aprila Ateg ES (man Vasope ORAL Uygula Su Ex mad Gastria Ateg E Ex mad Gastria Ateg E Man Ateg E Ex mad Gastria Ateg E Man Ateg E Ma	midej mi desteği essor kullanımı BESLENME RAL BESLENME n sib enen EN miktarı Nı miktarı ma has Nüfer ürün recidü NTERAL BESLENME enen PN miktarı Nı miktarı	Tech T	arth .	Tarih	Tarih	Tarih	T.
Entered Paramter Got.No. 410100 TTEPE ONIVERSITE Mastaneol Becleron openic a No: Cinaly statistics: O Yok Taneo clinic dykdod: child dy	Sentral Profilerii ESI HASTANELERII Devotas Birlind Devotas Birlind Destas Sentral DEST S. E. J. E. J. DAR. J. KISAH J. ENTERAL ENTERAL Metabolis Disponstremi Publisherii Disponstremi Publi	Boy - Kilor NRS 2002: Preafsümin II CRP III CRP III S. Yetarrül J- Au J- Rodyolpjii mi KOMPLİKALIY 1 110 110 110 110 110 110 110 110 110	4- Precop of Igiorensis oral also Igiorensis oral also Igiorensis oral also Igiorensis oral also Igiorensis oral also Igiorensis oral also Igiorensis oral also Igiorensis oral also Igiorensis oral also Igiorensis oral anticologia oral Igiorensis oral anticologia oral Igiorensis oral anticologia oral Igiorensis oral anticologia oral Igiorensis oral anticologia oral Igiorensis oral anticologia oral Igiorensis ora	HEMŞİRE İZI İzlam taribbi Çıkış taribbi Çıkış redeni: Pradiğinin s CRP son: 6- NT 2- Kun 8- Diğer PARENTERAL 0 Sürer 3- Postop 1 PARENTERAL 0 Sürer 3- Postop 1 PARENTERAL 0 Sürer 3- Postop 1 PARENTERAL 0 Sürer 3- Postop 1 PARENTERAL 0 Sürer 3- Postop 1 PARENTERAL 0 Sürer 3- Postop 1 PARENTERAL 0 Sürer 3- Postop 1 PARENTERAL 0 Sürer 3- Postop 1 PARENTERAL 0 Sürer 3- Postop 0 PARENTERAL 0 Sürer 3- Postop 0 PARENTERAL 0 PARENTE	LEM FORMU Senti S. Diğer O diestek L D-Periodinan S- (IV) F-Periodic S- (PICC) Cape: ENTERAK Engim Yolu Flabit D harima S- fairima S- fairima S- fairima S- fairima S- fairima S- fairima S- fairima	Ağırtık Ateş RB (men Solumu Vazope ORAL ENTE! EN ürü Hedefi Addığı FA med Gastrik PARE Hedefi Addığı FRedefi Addığı FRedefi Addığı FREDE ROJON R	metaliji essor kullanima BESLENME RAL BESLENME n odi soon EN miktari Un miktari ma hiss Suller Grön residia NTERAL BESLENME enin PN miktari 'N miktari IDIĞE stroytomil	Teris 1	irih :	Tarih	Tarih	Tack	70
Entered Paramter Forthol 11899 TTEPE ONIVERSITE Hastaneed Beckenn loyed: In No: Cinaly satabliber: O Yok Taneac ails dyklod: serilly yolu cally yol isverelly yolu cally yol isverelly yolu cally yol isverelly yolu cally yol isverelly yolu cally yol isverelly yolu cally yol isverelly yolu cally yol isverelly yolu cally yol isverelly yolu cally yol isverelly yolu cally yol isverelly yol	Sentral Profilerii ESI HASTANELERII Devotas Birlind Devotas Birlind Destas Sentral DEST S. E. J. E. J. DAR. J. KISAH J. ENTERAL ENTERAL Metabolis Disponstremi Publisherii Disponstremi Publi	Boy - Kilor NRS 2002: Preafsümin II CRP III CRP III S. Yetarrül J- Au J- Rodyolpjii mi KOMPLİKALIY 1 110 110 110 110 110 110 110 110 110	4- Proop of Spirensis oral also S- XXY 4- Proop of Spirensis oral also Spirensis oral also Spirensis ONLAR 1- Spirensis ONLA	HEMSIRE IZI Intern taribi: Chiq taribi: Chiq nedeni: Presidenin i CEP son: 6. NT 7-Kan FARNITEAL Sign: 1-Port 2 4-SeV 5 5-Capter PARNITEAL Sign:	LEM FORMU Sees 8: Diğer Sees 8: Diğer D. Mickenson 3- IVV S. Fernickal 6- PICC II Capit ENTERAC Erigim York C Fance C Falcons C Falco	Ağırtık Ateş ES (men Solumu Vazope ORAL ENTE! EN ürb Heddifi Addığı İs Ek mod Gastrik PARE Heddifi Addığı İs Feddifi Addığı İs Feddifi Addığı İs Feddifi Addığı İs CONAN Dren Flensil Rester Kolontu Gastz	midej mi desteği essor kullanımı BESLENME RAL BESLENME n sib enen EN miktarı Nı miktarı ma has Nüfer ürün recidü NTERAL BESLENME enen PN miktarı Nı miktarı	Tarih T	irb.	Tarih	Tarih	Tech.	7

Figure 2 . Follow up forms

intestinal failure in adults patients were classified as short bowel syndrome group [4]. Patients' demographic data, extent of surgery, intensive care unit and hospital length of stay (LOS), type of nutritional treatment, nutritional treatment duration, achieving nutritional goals, and 30-day and overall mortality rates were investigated.

SPSS software v23.0 (IBM Inc., Armonk, New York, USA) was used for statistical analysis. We used descriptive statics to analyze the demographic data; chi-squared tests were used for multiple proportions, and a p-value <0.05 was considered significant. Continuous numerical variables were not normally distributed, and we presented them as the median value via the Mann-Whitney U-test. Categorical data were presented with frequency (%) and compared by chi-squared testing.

Informed consent was obtained from the patients and the study was approved by Institutional Ethic Committee (GO16/65).

RESULTS

A total of 30 patients (19 males and 11 females) were diagnosed and hospitalized for AMI during the study period. Twenty-five patients had additional co-morbidities including atrial fibrillation, diabetes mellitus, deep venous thrombosis, mitral valve replacement, vasculitis, and malignancy. Twenty-

nine patients were operated on due to AMI, and one patient was followed up non- operatively with anticoagulation. Operative procedures were evaluated in three groups: 1. Massive small bowel \pm colon resection, 2. Segmental small bowel \pm colon resection, and 3. other surgical procedures. After resection, intestinal anastomoses were performed in 16 patients while in the remaining operations were completed with an ostomy.

Patient characteristics and surgical procedures are summarized in Table 1.

The median hospital LOS was 20 days (range: 1-220) and median intensive care unit LOS was 6.5 days (range: 6-206). The 30-day mortality rate was 37.9% (n= 11), and the overall hospital mortality rate was 53.3% (n=16).

Eighteen patients received nutritional treatment during hospitalization, and the median duration of this treatment was 18 days (range: 3-128). Twelve patients did not receive any nutritional intervention due to early mortality (n=6) and early return to oral intake (n=6); the median length of stay in these patients was 11 days (range: 1-26). The operative mortality and overall mortality of patients receiving nutritional treatment were 27% (n=5) and 50% (n=9), respectively. The median LOS of the patients receiving nutritional treatment was significantly higher than those who did not [28.5 (9-220) days and 11 (1-26) days respectively]. Parenteral

Table 1. Patient characteristics and surgical procedures

Patient Characteristics		Number (n)	Percentage (%)
Age (median, range)	64 (19-87)		
BMI	26.8 (15.0-35.1) kg/m ²		
Candau	Male	19	63%
Gender	Female	11	37%
Co-morbidities	Atrial fibrillation	5	16%
	Diabetes mellitus	5	16%
	Hypertension	10	32%
	Malignancy	6	20%
	Vascular diseases	6	20%
	Other diseases (Chronic renal failure, autoimmune diseases. etc.)	11	36%
Surgical procedures			
	Massive small bowel± colon resection	8	26%
	Segmental small bowel ±colon resection	16	53%
	Other surgical procedures (Primary repair, total colectomy, segmental colon resection)	5	16%

BMI: Body mass index

nutritional (72%, n=13) was the most commonly used route followed by enteral (17%, n=3) and enteral plus parenteral combination (11%, n=2).

For the patients receiving nutritional treatment, we aimed to reach 25 kcal/ kg/d energy and 1.5 gr/ kg/d protein depending on the patient's general condition. These target levels were only achieved in 11 patients (61%). The main reasons for the failure were fluid restriction and patient's hemodynamic instability. There was no significant difference between the patients whose treatment objectives were reached or failed in terms of LOS (p=0.375) or mortality [(p=0.630 (95% Cl0,237-10,809)] (Table 2).

In patients with short bowel syndrome, early mortality was seen in 1 of 8 patient (postoperative day 1). In addition to this, 4 patient died during the hospital course. Operative mortality rate was high as 62% (n=5). Five patients whose surgeries resulted in short bowel received only parenteral nutrition after clinical stabilization. All mortalities occurred in the parenteral nutrition group which progression to enteral or combined enteral plus parenteral nutrition was not possible.

DISCUSSION

Acute mesenteric ischemia is a surgical emergency with high mortality rates. To date no laboratory test can accurately diagnose the bowel ischemia or necrosis [5,6]. A high index of suspicion, early diagnosis, and prompt treatment are key factors for improved survival rates. Arterial emboli, thrombosis, venous infarction, and non-occlusive ischemia are the main causes of AMI [7]. Cardiac arrhythmia, endocarditis, vasculitis, cardiac failure, malignancies and hypercoagulability contribute to the disease process. Most patients have at least one co-morbidity as a risk factor for the development of bowel ischemia. Assessment of bowel viability by laparotomy or laparoscopy is indicated when overt peritoneal irritation signs are present. Reestablishment of vascular flow, resection of nonviable intestine, and preserving viable bowel are

the main goals of surgery [8]. Unfortunately, most patients in our series required bowel resection due to bowel necrosis and endovascular or open surgical revascularization techniques were not be possible. Late admission and delay in diagnosis are the main causes of this condition.

In our study, majority of patients received parenteral route alone (n= 13, 72%). This seems to be a deviation from recommendations. Guidelines recommend early enteral or combined nutrition for post-operative artificial nutrition after major abdominal surgery [9,10]. However, parenteral nutrition becomes necessary when enteral nutrition is not possible or inadequate due to impaired gastrointestinal function or presence of a high output stoma which are very common after surgery performed due to mesenteric ischemia. Two possible explanations of this high rate of parenteral route utilization in our study are; Patients whose operation resulted in short bowel syndrome require parenteral nutrition due to high stoma output or diarrhea at the early phase. Second, the high anastomosis rate and presence of intraabdominal infections may render the patients not to use enteral route for several days (n=16).

Meticulous monitoring is crucial to avoid complications. Target levels of 25kcal/k/d energy and 1.5 gr/kg/d protein may be slightly lower than the actual requirements [9]. On the other hand, over nutrition may which increase the energy expenditure, oxygen consumption and carbondioxide production and can be dangerous.

In this study, the patients who required parenteral nutrition have a longer LOS. Patients who did not receive nutritional treatment had little resections and could quickly return to oral intake. Those who survived the early post-operative period were prone to type II intestinal failure due to surgical trauma, pre-existing co-morbidities, and accompanying septic or metabolic complications [11,12]. These patients eventually need complex and long-term nutritional management, which prolongs the LOS [13].

Table 2. Mortality rates and length of stay of patients who received nutritional treatment.

	Mortality (%)	Median Length of Stay (range)
Nutritional goals achieved (n= 11)	6 (54%)	37 days (11-220)
Nutritional goals not achieved (n=7)	3 (42%)	25 days (9-93)

The main limitations of this study are small sample size and retrospective nature. Multicenter prospective trials are needed to establish adequate nutritional management of patients undergoing surgery for AMI.

CONCLUSION

The management of acute mesenteric ischemia patients is challenging. Nutritional treatment is one of the most crucial components of this treatment. Reaching the nutritional goals may not be possible in many patients. Individualized and meticulous

nutrition treatment may help to improve patient management.

CONFLICTS of INTEREST

The authors declare that there is no conflict of interest.

FUNDING

None

~ REFERENCES COM

- [1] Eslami MH, Rybin D, Doros G et.al. Mortality of acute mesenteric ischemia remains unchanged despite significant increase in utilization of endovascular techniques. Vascular. 2016; 24(1): 44-52. doi:10.1177/1708538115577730
- [2] Acosta S, Björck M. Acute thrombo-embolic occlusion of the superior mesenteric artery: A prospective study in a well defined population. EJVES. 2003; 26(2): 179-183. doi:https://doi.org/10.1053/ejvs.2002.1893
- [3] Nurkkala J, Kaakinen T, Vakkala M, et.al. Factors associated with discrepancy between prescribed and administered enteral nutrition in general ICU. Eur J Clin Nutr. 2020; 74(2): 248-254. doi: 10.1038/s41430-019-0451-8. Epub 2019 Jun 13. PMID: 31197219.
- [4] Pironi L, Arends J, Bozzetti F, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin.Nutr. 2016; 35(2): 247-307. doi:https://doi.org/10.1016/j.clnu.2016.01.020
- [5] Powell A, Armstrong P. Plasma biomarkers for early diagnosis of acute intestinal ischemia. Semin Vasc Surg. 2014; 27(3): 170-175. doi:https://doi.org/10.1053/j. semvascsurg.2015.01.008
- [6] Evennett NJ, Petrov MS, Mittal A et.al. Systematic Review and Pooled Estimates for the Diagnostic Accuracy of Serological Markers for Intestinal Ischemia. journal article. World J Surg. 2009; 33(7): 1374-1383. doi:10.1007/s00268-009-0074-7
- [7] Bala M, Kashuk J, Moore EE, et al. Acute mesenteric ischemia: guidelines of the World Society of Emergency

- Surgery. World J Emerg Surg. 2017; 12(1): 38. doi:10.1186/s13017-017-0150-5
- [8] Bala M, Kashuk J, Moore EE, et al. Acute mesenteric ischemia: guidelines of the World Society of Emergency Surgery. World J Emerg Surg. 2017; 12: 38-38. doi:10.1186/ s13017-017-0150-5
- [9] McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically III Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016; 40(2): 159-211. doi:10.1177/0148607115621863
- [10] Weimann A, Braga M, Carli F, et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr. 2017; 36(3): 623-650. doi:10.1016/j.clnu.2017.02.013
- [11] Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr. 2015; 34(2): 171-80. doi:10.1016/j.clnu.2014.08.017
- [12] Park WM, Gloviczki P, Cherry KJ, et al. Contemporary management of acute mesenteric ischemia: Factors associated with survival. J Vasc Surg. 2002; 35(3): 445-452. doi:https://doi.org/10.1067/mva.2002.120373
- [13] Klek S, Forbes A, Gabe S, et al. Management of acute intestinal failure: A position paper from the European Society for Clinical Nutrition and Metabolism (ESPEN) Special Interest Group. Clin Nutr. 2016; 35(6): 1209-1218. doi:10.1016/j.clnu.2016.04.009